NovoCure Announces Positive Phase 3 Trial Results

An announcement from NovoCure ( (NVCR) ) is now available.

On May 31, 2025, Novocure announced positive results from its Phase 3 PANOVA-3 clinical trial at the ASCO Annual Meeting, demonstrating that TTFields therapy, when combined with gemcitabine and nab-paclitaxel, significantly improves overall survival and extends pain-free survival for patients with unresectable, locally advanced pancreatic adenocarcinoma. The findings, which will support a Premarket Approval submission to the FDA, highlight TTFields’ potential to become a standard treatment for this challenging cancer type, marking a significant advancement in Novocure’s market positioning and offering hope for improved patient outcomes.

The most recent analyst rating on (NVCR) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.

Spark’s Take on NVCR Stock

According to Spark, TipRanks’ AI Analyst, NVCR is a Neutral.

NovoCure’s stock score reflects its moderate revenue growth and strategic expansions, which are overshadowed by significant challenges such as profitability issues, cash flow concerns, and negative valuation metrics. While the company shows potential with its CE Mark approval and expansion efforts, these positive developments are offset by ongoing financial struggles and bearish technical indicators.

To see Spark’s full report on NVCR stock, click here.

More about NovoCure

Novocure is a company operating in the medical technology industry, primarily focusing on the development and commercialization of Tumor Treating Fields (TTFields) therapy. This therapy is used for treating various types of cancer, with a significant focus on pancreatic cancer, as evidenced by their recent clinical trials.

Average Trading Volume: 891,436

Technical Sentiment Signal: Sell

Current Market Cap: $2.13B

See more insights into NVCR stock on TipRanks’ Stock Analysis page.